These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 21717445)

  • 1. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.
    Schwartz MD; Isaacs C; Graves KD; Poggi E; Peshkin BN; Gell C; Finch C; Kelly S; Taylor KL; Perley L
    Cancer; 2012 Jan; 118(2):510-7. PubMed ID: 21717445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
    Singh K; Lester J; Karlan B; Bresee C; Geva T; Gordon O
    Am J Obstet Gynecol; 2013 Apr; 208(4):329.e1-6. PubMed ID: 23333547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling.
    Tong A; Kelly S; Nusbaum R; Graves K; Peshkin BN; Valdimarsdottir HB; Wood M; McKinnon W; Garber J; McCormick SR; Jandorf L; Schwartz MD
    Psychooncology; 2015 Jan; 24(1):33-9. PubMed ID: 24839250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.
    Chai X; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Tung N; Weitzel JN; Couch FJ; Hulick PJ; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Blum JL; Domchek SM; Chen J; Rebbeck TR
    Breast Cancer Res Treat; 2014 Nov; 148(2):397-406. PubMed ID: 25311111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uptake of risk-reducing surgery in BRCA gene carriers in Wales, UK.
    Long J; Evans TG; Bailey D; Lewis MH; Gower-Thomas K; Murray A
    Breast J; 2018 Jul; 24(4):580-585. PubMed ID: 29286205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
    Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers.
    Chen Y; Bancroft E; Ashley S; Arden-Jones A; Thomas S; Shanley S; Saya S; ; Wakeling E; Eeles R
    Fam Cancer; 2014 Jun; 13(2):197-203. PubMed ID: 24389956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations.
    Julian-Reynier C; Mancini J; Mouret-Fourme E; Gauthier-Villars M; Bonadona V; Berthet P; Fricker JP; Caron O; Luporsi E; Noguès C
    Eur J Hum Genet; 2011 May; 19(5):500-6. PubMed ID: 21267012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic BRCA1/2 variants evaluated at a large urban comprehensive cancer center.
    Assad H; Levitin M; Petrucelli N; Manning M; Thompson HS; Chen W; Jang H; Simon MS
    Breast Cancer Res Treat; 2024 Jul; 206(2):261-272. PubMed ID: 38605155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk management options elected by women after testing positive for a BRCA mutation.
    Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
    Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers.
    Beattie MS; Crawford B; Lin F; Vittinghoff E; Ziegler J
    Genet Test Mol Biomarkers; 2009 Feb; 13(1):51-6. PubMed ID: 19309274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
    Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR
    JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1/2 test results impact risk management attitudes, intentions, and uptake.
    O'Neill SC; Valdimarsdottir HB; Demarco TA; Peshkin BN; Graves KD; Brown K; Hurley KE; Isaacs C; Hecker S; Schwartz MD
    Breast Cancer Res Treat; 2010 Dec; 124(3):755-64. PubMed ID: 20383578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
    Gamble C; Havrilesky LJ; Myers ER; Chino JP; Hollenbeck S; Plichta JK; Kelly Marcom P; Shelley Hwang E; Kauff ND; Greenup RA
    Ann Surg Oncol; 2017 Oct; 24(11):3116-3123. PubMed ID: 28699130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
    Anderson K; Jacobson JS; Heitjan DF; Zivin JG; Hershman D; Neugut AI; Grann VR
    Ann Intern Med; 2006 Mar; 144(6):397-406. PubMed ID: 16549852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uptake and efficacy of bilateral risk reducing surgery in unaffected female
    Marcinkute R; Woodward ER; Gandhi A; Howell S; Crosbie EJ; Wissely J; Harvey J; Highton L; Murphy J; Holland C; Edmondson R; Clayton R; Barr L; Harkness EF; Howell A; Lalloo F; Evans DG
    J Med Genet; 2022 Feb; 59(2):133-140. PubMed ID: 33568438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels.
    Crosbie EJ; Flaum N; Harkness EF; Clayton RD; Holland C; Martin-Hirsch P; Wood N; Keating P; Woodward ER; Lalloo F; Donnai P; Edmondson RJ; Evans DG
    Int J Cancer; 2021 Mar; 148(5):1155-1163. PubMed ID: 33152107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.